Arbutus Biopharma (NASDAQ:ABUS) reported Q1 EPS of ($0.11), $0.05 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $12.6 million versus the consensus...
(Reuters) - Alnylam Pharmaceuticals Inc on Thursday filed lawsuits in Delaware federal court against Pfizer Inc (NYSE:PFE) and Moderna (NASDAQ:MRNA) Inc, claiming their...
Investing.com – U.S. stocks were lower after the close on Wednesday, as losses in the Consumer Services, Technology and Telecoms sectors led shares lower. At the close in NYSE,...
The S&P and NASDAQ took small steps back from record highs on Tuesday in preparation for a deluge of Big Tech data that began after the bell. Investors are feeling pretty...
The major indices added another 1% on Thursday and moved into Friday’s session with robust gains for the first week of February… along with a couple new all-time...
1. Arbutus Biopharma Corporation (ABUS) Arbutus Biopharma (NASDAQ:ABUS) has had a fantastic run since Oct, going from under a dollar, all the way up to 3 3/4, it consolidated in...
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company’s research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Sell | Sell | Strong Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 102.10 | 102.98 | 97.54 | +7.86 | +8.34% | 109.92M | NASDAQ | |||
| 0.173 | 0.18 | 0.1721 | +0.0003 | +0.17% | 691.17K | NYSE | |||
| 1.31 | 1.53 | 1.22 | +0.27 | +25.95% | 65.98M | NASDAQ | |||
| 38.56 | 38.85 | 37.64 | +1.05 | +2.81% | 6.24M | NYSE | |||
| 8.00 | 8.04 | 7.94 | +0.15 | +1.98% | 3.20M | NASDAQ | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 8.31 | 8.44 | 8.14 | +0.18 | +2.21% | 4.05M | NYSE | |||
| 13.60 | 14.81 | 13.02 | -0.30 | -2.16% | 4.23M | NYSE | |||
| 1.175 | 1.20 | 1.11 | +0.0850 | +7.80% | 7.07M | NYSE | |||
| 163.04 | 163.72 | 160.28 | +1.53 | +0.95% | 478.35K | NYSE | |||
| 90.70 | 94.48 | 89.74 | +4.22 | +4.88% | 20.61M | NYSE | |||
| 0.814 | 0.852 | 0.81 | +0.004 | +0.51% | 538.80K | NASDAQ | |||
| 5.78 | 5.83 | 5.30 | 0.00 | 0.00% | 0.00 | NASDAQ | |||
| 46.88 | 47.48 | 44.52 | +2.63 | +5.94% | 3.29M | NYSE | |||
| 4.13 | 4.22 | 3.98 | +0.09 | +2.23% | 370.54K | NASDAQ |